Coeptis Therapeutics, a biopharmaceutical company developing cell therapy for cancer, autoimmune, and infectious diseases, has announced the acquisition of the NexGenAI Affiliates Network platform.
Pennsylvania-based Coeptis Therapeutics has also launched Coeptis Technologies, a new division designed to drive the company’s growth potential.
The financial details of the acquisition were not revealed.
The NexGenAI Affiliates Network platform was developed by NexGenAI Solutions Group and its affiliates.
NexGenAI Holding Group, along with its majority-owned subsidiary NexGenAI Solutions Group, has developed a proprietary suite of advanced tools powering the NexGenAI Affiliates Network platform.
Featuring artificial intelligence (AI)-driven marketing software and robotic process automation capabilities, these tools are designed to optimise campaigns, streamline operations, and deliver actionable, data-driven insights.
NexGenAI’s platform offers AI solutions that transform business operations across various sectors including the highly regulated biotech, pharmaceutical, and multi-level marketing (MLM) industries.
By leveraging AI, NexGenAI helps companies automate processes, enhance efficiency, and drive sustainable growth.
NexGenAI Affiliates Network platform lead advisory Anshuman Dash said: “The integration of NexGenAI’s innovative AI-powered marketing solutions with Coeptis Therapeutics’ forward-thinking approach marks a transformative step forward.
“This acquisition aligns nicely with Coeptis’ mission to drive innovation in highly regulated industries, revolutionise marketing strategies and operational efficiencies and ultimately deliver greater value to the partners and the industries served.”
This acquisition is expected to enable Nasdaq-listed Coeptis Therapeutics to use advanced technologies and drive innovation in the biopharmaceutical sector.
The biopharmaceutical company aims to equip companies with advanced tools to tackle marketing challenges in competitive and highly regulated industries using NexGenAI’s AI-powered marketing solutions.
Coeptis Therapeutics president and CEO Dave Mehalick said: “We are excited to integrate the NexGenAI Affiliates Network platform and its AI and RPA-driven tools into our offerings.
“In industries like biotech, pharma, and MLM, where competition is so high and regulatory challenges are complex, having advanced tools to optimise marketing, streamline operations, and drive measurable results is critical.”
Coeptis Therapeutics’ portfolio also includes assets licensed from Deverra Therapeutics, such as an allogeneic cellular immunotherapy platform and DVX201, a clinical-stage, unmodified natural killer cell therapy.
The biopharmaceutical company is also developing SNAP-CAR, a universal multi-antigen CAR technology licensed from the University of Pittsburgh, and GEAR cell therapy and companion diagnostic platforms in partnership with VyGen-Bio and researchers at the Karolinska Institute.
